There is lower incidence of nonlacunar covert infarcts among patients with cryptogenic stroke and atrial cardiopathy treated with apixaban.

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients ...

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 ...

Apixaban may be safer and more effective than rivaroxaban for treating nonvalvular atrial fibrillation, a new observational study suggests. But some outside experts are unconvinced by the data.

A total of 1,350 patients prescribed apixaban were identified, of which 291 had received a concomitant cardiac P-gp inhibitor. The data indicated no significant differences in bleeding rates for ...

Although apixaban caused much lower rates of major bleeding in frail patients when compared to Coumadin (eg, 40.7 such events per 1,000 person-years for dabigatran and 83.4 such events per 1,000 ...